Global Cancer Vaccines Market 2021

January 2022 | 13 pages | ID: GABB8D44FB64EN
StrategyHelix Inc

Abstracts

According to a report by StrategyHelix, the global cancer vaccines market is set to increase by US$ 2,992 million during 2021-2027, growing at a CAGR of 8.2% during the forecast period. Increase in prevalence of cancer worldwide, rising investments and government funding in the development of cancer vaccines, rise in development of new cancer vaccines, launch and approval of new cancer vaccines in the market are expected to boost the market growth in the coming years.

The report provides up-to-date market size data for period 2017-2020 and forecast to 2027 covering key market aspects like sales value for cancer vaccines. The global cancer vaccines market is segmented on the basis of product, application, technology, and region. On the basis of product, the global cancer vaccines market has been segmented into preventative vaccines, therapeutic vaccines. Among these, the preventative vaccines segment was accounted for the highest revenue generator in 2020. By application, the global cancer vaccines market has been segmented into cervical cancer, liver cancer, prostate cancer, others. The cervical cancer segment is estimated to account for the largest share of the global cancer vaccines market. Based on technology, the global cancer vaccines market is categorized into dendritic cells (DC) cancer vaccines, recombinant cancer vaccines, antigen/adjuvant cancer vaccines, viral vector & DNA cancer vaccines. Geographically, the global cancer vaccines market is segmented into North America, Asia Pacific, Europe, Rest of the World (ROW).

The global cancer vaccines market is highly competitive. The cancer vaccines market is dominated by key players, which are Amgen Inc., Anixa Biosciences Inc. (ANIX), Dendreon Corporation, Dendreon Pharmaceuticals LLC, eTheRNA immunotherapies NV, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Immunicum AB, Inovio Pharmaceuticals Inc., Merck & Co. Inc., Moderna Inc., OSE Immunotherapeutics SA, Providence Therapeutics Holdings Inc., Sanofi SA, UbiVac Inc., Vaccinogen Inc.

Report Scope
Product: preventative vaccines, therapeutic vaccines
Application: cervical cancer, liver cancer, prostate cancer, others
Technology: dendritic cells (DC) cancer vaccines, recombinant cancer vaccines, antigen/adjuvant cancer vaccines, viral vector & DNA cancer vaccines
Region: North America, Asia Pacific, Europe, Rest of the World (ROW)
Years considered: this report covers the period 2017 to 2027

Key Benefits for Stakeholders
Get a comprehensive picture of the global cancer vaccines market
Pinpoint growth sectors and trends for investment

Contents

PART 1. INTRODUCTION

Scope of the study
Study period
Geographical scope
Research methodology

PART 2. CANCER VACCINES MARKET OVERVIEW

PART 3. MARKET BREAKDOWN BY PRODUCT

Preventative vaccines
Therapeutic vaccines

PART 4. MARKET BREAKDOWN BY APPLICATION

Cervical cancer
Liver cancer
Prostate cancer
Others

PART 5. MARKET BREAKDOWN BY TECHNOLOGY

Dendritic cells (DC) cancer vaccines
Recombinant cancer vaccines
Antigen/adjuvant cancer vaccines
Viral vector & DNA cancer vaccines

PART 6. MARKET BREAKDOWN BY REGION

North America
Asia Pacific
Europe
Rest of the World (ROW)

PART 7. KEY COMPANIES

Amgen Inc.
Anixa Biosciences, Inc. (ANIX)
Dendreon Corporation
Dendreon Pharmaceuticals LLC
eTheRNA immunotherapies NV
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline plc
Immunicum AB
Inovio Pharmaceuticals, Inc.
Merck & Co., Inc.
Moderna, Inc.
OSE Immunotherapeutics SA
Providence Therapeutics Holdings Inc.
Sanofi SA
UbiVac, Inc.
Vaccinogen Inc.
About StrategyHelix
Disclaimer